Overview: Bone Marrow Trephine Biopsy TestIntroduction: The Bone Marrow Trephine Biopsy Test examines bone marrow tissue to diagnose blood cancers or disorders, causing fatigue or bone pain. Following 2023 ASH guidelines, it uses microscopy for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in histopathology for patients with suspected blood disorders.
Other Names: Bone Marrow Biopsy Assay, Marrow Histology Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Bone marrow biopsy began in the 1900s with marrow aspiration. Trephine biopsy techniques improved in the 1970s, and by the 2000s, advanced staining enhanced cancer diagnosis.
Purpose: Diagnoses blood cancers or disorders, guides treatment, and monitors marrow pathology in patients with fatigue or bone pain.
Test Parameters: 1. Bone Marrow Trephine Biopsy
Pretest Condition: No fasting required. Collect bone marrow under local anesthesia. Report symptoms like fatigue or bone pain, and list medications like chemotherapy.
Specimen: 0.5-2 cma³ bone marrow (sterile container). Collect via trephine biopsy. Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, bone pain, or family history of blood cancers. Include current medications, especially chemotherapy or growth factors.
Consent: Written consent required, detailing the tests purpose, procedural risks, and potential need for cancer treatment.
Procedural Considerations: Uses microscopy to examine bone marrow tissue. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Inadequate sample size or improper fixation can affect results. Recent chemotherapy may alter marrow morphology.
Clinical Significance: Abnormal marrow findings confirm leukemia or myelodysplasia, prompting chemotherapy or transplant. Normal results suggest alternative diagnoses.
Specialist Consultation: Consult a hematologist for result interpretation. An oncologist referral is advised for cancer cases.
Additional Supporting Tests: Peripheral blood smear, flow cytometry, or cytogenetic testing to confirm blood disorders or assess disease extent.
Test Limitations: Sampling errors may miss focal disease. Results require clinical correlation with other tests.
References: ASH Hematology Guidelines, 2023; Blood, Tefferi A, 2022.
